Search PubMed:   

Publikationen 2008

Editorials

  1. Altschmied J, Haendeler J (2008) A new kid on the block: PKD1: a promising target for antiangiogenic therapy? ARTERIOSCL THROM VAS, 28(10): 1689-90
    Letter
  2. Burmeister T, Schwartz S, Bartram CR, Gökbuget N, Hoelzer D, Thiel E, GMALL study group (2008) Patients' age and BCR-ABL frequency in adult B-precursor ALL: a retrospective analysis from the GMALL study group. BLOOD, 112(3): 918-9
  3. Schindewolf M, Ludwig RJ, Wolter M, Himsel A, Zgouras D, Kaufmann R, Boehncke WH, Lindhoff-Last E (2008) Tolerance of fondaparinux in patients with generalized contact dermatitis to heparin. J Eur Acad Dermatol Venereol, 22(3): 378-80

Originalarbeiten

  1. Agrawal S, Koschmieder S, Bäumer N, Reddy NG, Berdel WE, Müller-Tidow C, Serve H (2008) Pim2 complements Flt3 wild-type receptor in hematopoietic progenitor cell transformation. LEUKEMIA, 22(1): 78-86
  2. Antiretroviral Therapy Cohort Collaboration. (2008) Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. LANCET, 372(9635): 293-9
  3. Antiretroviral-Therapy-Cohort-Collaboration-(ART-CC), Mugavero MJ, May M, Harris R, Saag MS, Costagliola D, Egger M, Phillips A, Günthard HF, Dabis F, Hogg R, de Wolf F, Fatkenheuer G, Gill MJ, Justice A, D'Arminio Monforte A, Lampe F, Miró JM, Staszewski S, Sterne JA (2008) Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice? AIDS, 22(18): 2481-92
  4. Autran B, Murphy RL, Costagliola D, Tubiana R, Clotet B, Gatell J, Staszewski S, Wincker N, Assoumou L, El-Habib R, Calvez V, Walker B, Katlama C, ORVACS Study Group (2008) Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452). AIDS, 22(11): 1313-22
  5. Baak U, Gökbuget N, Orawa H, Schwartz S, Hoelzer D, Thiel E, Burmeister T, German Multicenter ALL Study Group (2008) Thymic adult T-cell acute lymphoblastic leukemia stratified in standard- and high-risk group by aberrant HOX11L2 expression: experience of the German multicenter ALL study group. LEUKEMIA, 22(6): 1154-60
  6. Bangsow T, Baumann E, Bangsow C, Jaeger MH, Pelzer B, Gruhn P, Wolf S, von Melchner H, Stanimirovic DB (2008) The epithelial membrane protein 1 is a novel tight junction protein of the blood-brain barrier. J CEREBR BLOOD F MET, 28(6): 1249-60
  7. Bannister WP, Ruiz L, Cozzi-Lepri A, Mocroft A, Kirk O, Staszewski S, Loveday C, Karlsson A, Monforte A, Clotet B, Lundgren JD, EuroSIDA study group (2008) Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA. AIDS, 22(3): 367-76
  8. Baeumler J, Szuhai K, Falkenburg JH, van Schie ML, Ottmann OG, Nijmeijer BA (2008) Establishment and cytogenetic characterization of a human acute lymphoblastic leukemia cell line (ALL-VG) with ETV6/ABL1 rearrangement. Cancer Genet Cytogenet, 185(1): 37-42
  9. Beck O, Koehl U, Tramsen L, Mousset S, Latgé JP, Müller K, Schwabe D, Bader P, Klingebiel T, Lehrnbecher T (2008) Enumeration of functionally active anti-Aspergillus T-cells in human peripheral blood. J IMMUNOL METHODS, 335(1-2): 41-5
  10. Beissert T, Hundertmark A, Kaburova V, Travaglini L, Mian AA, Nervi C, Ruthardt M (2008) Targeting of the N-terminal coiled coil oligomerization interface by a helix-2 peptide inhibits unmutated and imatinib-resistant BCR/ABL. INT J CANCER, 122(12): 2744-52
  11. Bergmann L, Aamdal S, Marreaud S, Lacombe D, Herold M, Yamaguchi T, Wilhelm-Ogunbiyi K, Lentzen H, Zwierzina H, European Organisation for Research and Treatment of Cancer (2008) Phase I trial of r viscumin (INN: aviscumine) given subcutaneously in patients with advanced cancer: a study of the European Organisation for Research and Treatment of Cancer (EORTC protocol number 13001). EUR J CANCER, 44(12): 1657-62
  12. Bickel M, Zangos S, Lutz T, Eisen J, Knecht G, Goebel FD, Crespi CM, Jacobi V, Staszewski S, Klauke S (2008) Long-term effect on body composition and metabolic parameters after treatment with recombinant human growth hormone (r-hGH) in HIV-1 infected patients with lipodystrophy. SCAND J INFECT DIS, 40(1): 36-9
  13. Binninger-Schinzel D, Müller D, Wolf T, Krause B, Meye B, Winskowsky G, Raupp S, Norley S, Brodt R, Werner A (2008) Characterization of a chemokine receptor CCR5-negative T cell line and its use in determining human immunodeficiency virus type 1 phenotype. J MED VIROL, 80(2): 192-200
  14. Böiers U, Lanig H, Sehnert B, Holmdahl R, Burkhardt H (2008) Collagen type II is recognized by a pathogenic antibody through germline encoded structures. EUR J IMMUNOL, 38(10): 2784-95
  15. Brixner V, Richter R, Bader P, Seifried E, Seidl C (2008) A new HLA-B*08 allele, HLA-B*0828, found in two voluntary stem cell donors. TISSUE ANTIGENS, 71(5): 482-3
  16. Brück P, Ramos-Lopez E, Bartsch W, Böhme A, Badenhoop K (2008) TIM-3 polymorphisms in type 1 diabetes families. J HUM GENET, 53(6): 559-64
  17. Bulk E, Hascher A, Liersch R, Mesters RM, Diederichs S, Sargin B, Gerke V, Hotfilder M, Vormoor J, Berdel WE, Serve H, Müller-Tidow C (2008) Adjuvant therapy with small hairpin RNA interference prevents non-small cell lung cancer metastasis development in mice. CANCER RES, 68(6): 1896-904
  18. Cornely OA, Böhme A, Reichert D, Reuter S, Maschmeyer G, Maertens J, Buchheidt D, Paluszewska M, Arenz D, Bethe U, Effelsberg J, Lövenich H, Sieniawski M, Haas A, Einsele H, Eimermacher H, Martino R, Silling G, Hahn M, Wacker S, Ullmann AJ, Karthaus M, Multinational Case Registry of the Infectious Diseases Working Party of the German Society for Hematology and Oncology (2008) Risk factors for breakthrough invasive fungal infection during secondary prophylaxis. J ANTIMICROB CHEMOTH, 61(4): 939-46
  19. Distler O, Behrens F, Pittrow D, Huscher D, Denton CP, Foeldvari I, Humbert M, Matucci-Cerinic M, Nash P, Opitz CF, Rubin LJ, Seibold JR, Furst DE, EPOSS-Omeract-Group (2008) Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: a Delphi consensus study with cluster analysis. ARTH RHEUM/AR C RES, 59(6): 867-75
  20. Ernst T, Erben P, Müller MC, Paschka P, Schenk T, Hoffmann J, Kreil S, La Rosée P, Hehlmann R, Hochhaus A (2008) Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib. HAEMATOL-HEMATOL J, 93(2): 186-92
  21. Floss T, Schnütgen F (2008) Conditional gene trapping using the FLEx system. Methods Mol Biol, 435: 127-38
  22. Fox Z, Phillips A, Cohen C, Neuhaus J, Baxter J, Emery S, Hirschel B, Hullsiek KH, Stephan C, Lundgren J, SMART Study Group (2008) Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen. AIDS, 22(17): 2279-89
  23. Geretti AM, Smith C, Haberl A, Garcia-Diaz A, Nebbia G, Johnson M, Phillips A, Staszewski S (2008) Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy. ANTIVIR THER, 13(7): 927-36
  24. Gladman DD, Rahman P, Krueger GG, Mease PJ, Qureshi AA, Dutz JP, Lindqvist U, Carneiro S, Helliwell PS, Ujfalussy I, Gottlieb AB, Behrens F, Ståhle M (2008) Clinical and genetic registries in psoriatic disease. J RHEUMATOL, 35(7): 1458-63
  25. Graff J, von Hentig N, Kuczka K, Angioni C, Gute P, Klauke S, Babacan E, Harder S (2008) Significant effects of tipranavir on platelet aggregation and thromboxane B2 formation in vitro and in vivo. J ANTIMICROB CHEMOTH, 61(2): 394-399
  26. Guardiola-Serrano F, Haendeler J, Lukosz M, Sturm K, Melchner H, Altschmied J (2008) Gene trapping identifies a putative tumor suppressor and a new inducer of cell migration. BIOCHEM BIOPH RES CO, 376(4): 748-52
  27. Gueller S, Gery S, Nowak V, Liu L, Serve H, Koeffler HP (2008) Adaptor protein Lnk associates with Tyr(568) in c-Kit. BIOCHEM J, 415(2): 241-5
  28. Haritunians T, Gueller S, O'Kelly J, Ilaria R, Koeffler HP (2008) Novel acyl sulfonamide LY573636-sodium: effect on hematopoietic malignant cells. ONCOL REP, 20(5): 1237-42
  29. Haritunians T, Gueller S, Zhang L, Badr R, Yin D, Xing H, Fung MC, Koeffler HP (2008) Cucurbitacin B induces differentiation, cell cycle arrest, and actin cytoskeletal alterations in myeloid leukemia cells. LEUKEMIA RES, 32(9): 1366-73
  30. Hoemme C, Peerzada A, Behre G, Wang Y, McClelland M, Nieselt K, Zschunke M, Disselhoff C, Agrawal S, Isken F, Tidow N, Berdel WE, Serve H, Muller-Tidow C (2008) Chromatin modifications induced by PML-RAR{alpha} repress critical targets in leukemogenesis as analyzed by ChIP-Chip. BLOOD, 111(5): 2887-95
  31. Hourfar MK, Jork C, Schottstedt V, Weber-Schehl M, Brixner V, Busch MP, Geusendam G, Gubbe K, Mahnhardt C, Mayr-Wohlfart U, Pichl L, Roth WK, Schmidt M, Seifried E, Wright DJ (2008) Experience of German Red Cross blood donor services with nucleic acid testing: results of screening more than 30 million blood donations for human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus. TRANSFUSION, 48(8): 1558-66
  32. Hüffmeier U, Böiers U, Lascorz J, Reis A, Burkhardt H (2008) Loss-of-function mutations in the filaggrin gene: no contribution to disease susceptibility, but to autoantibody formation against citrullinated peptides in early rheumatoid arthritis. ANN RHEUM DIS, 67(1): 131-3
  33. Isken F, Steffen B, Merk S, Dugas M, Markus B, Tidow N, Zühlsdorf M, Illmer T, Thiede C, Berdel WE, Serve H, Müller-Tidow C (2008) Identification of acute myeloid leukaemia associated microRNA expression patterns. BRIT J HAEMATOL, 140(2): 153-61
  34. Jakob S, Schroeder P, Lukosz M, Büchner N, Spyridopoulos I, Altschmied J, Haendeler J (2008) Nuclear protein tyrosine phosphatase Shp-2 is one important negative regulator of nuclear export of telomerase reverse transcriptase. J BIOL CHEM, 283(48): 33155-61
  35. Jelinek T, Schade Larsen C, Siikamaki H, Myrvang B, Chiodini P, Gascon J, Visser L, Kapaun A, Just-Nubling G (2008) European cluster of imported falciparum malaria from Gambia. Euro Surveill, 13(51): 19077
  36. Jilani I, Kantarjian H, Faraji H, Gorre M, Cortes J, Ottmann O, Bhalla K, O'Brien S, Giles F, Albitar M (2008) An immunological method for the detection of BCR-ABL fusion protein and monitoring its activation. LEUKEMIA RES, 32(6): 936-43
  37. Jilani I, Kantarjian H, Gorre M, Cortes J, Ottmann O, Bhalla K, Giles FJ, Albitar M (2008) Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy. LEUKEMIA RES, 32(4): 643-9
  38. Kessler T, Mohr M, Müller-Tidow C, Krug U, Brunnberg U, Mohr B, Schliemann C, Sauerland C, Serve H, Büchner T, Berdel WE, Mesters RM (2008) Amsacrine containing induction therapy in elderly AML patients: Comparison to standard induction regimens in a matched-pair analysis. LEUKEMIA RES, 32(3): 491-4
  39. Khaykin P, Postel N, Reeb I, Staszewski S (2008) Switch to efavirenz (EFV) after protease-inhibitor (PI)-failure: explorative analysis of outcome by baseline viral VS tolerability failure. EUR J MED RES, 13(4): 169-72
  40. Klarmann D; Martinez Saguer I; Funk MB; Knoefler R; von Hentig N; Heller C; Kreuz W (2008) Immune tolerance induction with mycophenolate-mofetil in two children with haemophilia B and inhibitor. HAEMOPHILIA, 14(1): 44-9
  41. Kucheryava N, Bowen JK, Sutherland PW, Conolly JJ, Mesarich CH, Rikkerink EH, Kemen E, Plummer KM, Hahn M, Templeton MD (2008) Two novel Venturia inaequalis genes induced upon morphogenetic differentiation during infection and in vitro growth on cellophane. FUNGAL GENET BIOL, 45(10): 1329-39
  42. Langer C, Radmacher MD, Ruppert AS, Whitman SP, Paschka P, Mrózek K, Baldus CD, Vukosavljevic T, Liu CG, Ross ME, Powell BL, de la Chapelle A, Kolitz JE, Larson RA, Marcucci G, Bloomfield CD, Cancer and Leukemia Group B (CALGB) (2008) High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study. BLOOD, 111(11): 5371-9
  43. La Rosée P, Holm-Eriksen S, Konig H, Härtel N, Ernst T, Debatin J, Mueller MC, Erben P, Binckebanck A, Wunderle L, Shou Y, Dugan M, Hehlmann R, Ottmann OG, Hochhaus A (2008) Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib. HAEMATOL-HEMATOL J, 93(5): 765-9
  44. le Coutre P, Ottmann OG, Giles F, Kim DW, Cortes J, Gattermann N, Apperley JF, Larson RA, Abruzzese E, O'Brien SG, Kuliczkowski K, Hochhaus A, Mahon FX, Saglio G, Gobbi M, Kwong YI, Baccarani M, Hughes T, Martinelli G, Radich JP, Zheng M, Shou Y, Kantarjian H (2008) Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated phase chronic myelogenous leukemia. BLOOD, 111(4): 1834-9
  45. Liebner S, Corada M, Bangsow T, Babbage J, Taddei A, Czupalla CJ, Reis M, Felici A, Wolburg H, Fruttiger M, Taketo MM, von Melchner H, Plate KH, Gerhardt H, Dejana E (2008) Wnt/beta-catenin signaling controls development of the blood-brain barrier. J CELL BIOL, 183(3): 409-17
  46. Lokhorst HM, Schmidt-Wolf I, Sonneveld P, van der Holt B, Martin H, Barge R, Bertsch U, Schlenzka J, Bos GM, Croockewit S, Zweegman S, Breitkreuz I, Joosten P, Scheid C, van Marwijk-Kooy M, Salwender HJ, van Oers MH, Schaafsma R, Naumann R, Sinnige H, Blau I, Verhoef G, de Weerdt O, Wijermans P, Wittebol S, Duersen U, Vellenga E, Goldschmidt H, Dutch-Belgian-HOVON, German GMMG (2008) Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma. HAEMATOL-HEMATOL J, 93(1): 124-7
  47. Lorenz MW, Stephan C, Harmjanz A, Staszewski S, Buehler A, Bickel M, von Kegler S, Ruhkamp D, Steinmetz H, Sitzer M (2008) Both long-term HIV infection and highly active antiretroviral therapy are independent risk factors for early carotid atherosclerosis. ATHEROSCLEROSIS, 196(2): 720-6
  48. Malysheva OA, Wahle M, Wagner U, Pierer M, Arnold S, Häntzschel H, Baerwald CG (2008) Low-dose prednisolone in rheumatoid arthritis: adverse effects of various disease modifying antirheumatic drugs. J RHEUMATOL, 35(6): 979-85
  49. Malysheva O, Pierer M, Wagner U, Wahle M, Wagner U, Baerwald CG (2008) Association between beta2 adrenergic receptor polymorphisms and rheumatoid arthritis in conjunction with human leukocyte antigen (HLA)-DRB1 shared epitope. ANN RHEUM DIS, 67(12): 1759-64
  50. Marcucci G, Maharry K, Radmacher MD, Mrózek K, Vukosavljevic T, Paschka P, Whitman SP, Langer C, Baldus CD, Liu CG, Ruppert AS, Powell BL, Carroll AJ, Caligiuri MA, Kolitz JE, Larson RA, Bloomfield CD (2008) Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study. J CLIN ONCOL, 26(31): 5078-87
  51. Marcucci G, Radmacher MD, Maharry K, Mrózek K, Ruppert AS, Paschka P, Vukosavljevic T, Whitman SP, Baldus CD, Langer C, Liu CG, Carroll AJ, Powell BL, Garzon R, Croce CM, Kolitz JE, Caligiuri MA, Larson RA, Bloomfield CD (2008) MicroRNA expression in cytogenetically normal acute myeloid leukemia. NEW ENGL J MED, 358(18): 1919-28
  52. Metzeler KH, Hummel M, Bloomfield CD, Spiekermann K, Braess J, Sauerland MC, Heinecke A, Radmacher M, Marcucci G, Whitman SP, Maharry K, Paschka P, Larson RA, Berdel WE, Büchner T, Wörmann B, Mansmann U, Hiddemann W, Bohlander SK, Buske C, Cancer and Leukemia Group B, German AML Cooperative Group (2008) An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia. BLOOD, 112(10): 4193-201
  53. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A, RECORD-1-Study-Group (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. LANCET, 372(9637): 449-56
  54. Mrózek K, Marcucci G, Paschka P, Bloomfield CD (2008) Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia. CURR OPIN ONCOL, 20(6): 711-8
  55. Nandakumar KS, Bajtner E, Hill L, Böhm B, Rowley MJ, Burkhardt H, Holmdahl R (2008) Arthritogenic antibodies specific for a major type II collagen triple-helical epitope bind and destabilize cartilage independent of inflammation. ARTH RHEUM/AR C RES, 58(1): 184-96
  56. Neubauer A, Maharry K, Mrózek K, Thiede C, Marcucci G, Paschka P, Mayer RJ, Larson RA, Liu ET, Bloomfield CD (2008) Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study. J CLIN ONCOL, 26(28): 4603-9
  57. Paschka P, Marcucci G, Ruppert AS, Whitman SP, Mrózek K, Maharry K, Langer C, Baldus CD, Zhao W, Powell BL, Baer MR, Carroll AJ, Caligiuri MA, Kolitz JE, Larson RA, Bloomfield CD (2008) Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J CLIN ONCOL, 26(28): 4595-602
  58. Pelz-Ackermann O, Cross M, Pfeifer H, Deininger M, Wang SY, Al-Ali HK, Niederwieser D, Lange T (2008) Highly sensitive and quantitative detection of BCR-ABL kinase domain mutations by ligation PCR. LEUKEMIA, 22(12): 2288-91
  59. Petrova TV, Nykänen A, Norrmén C, Ivanov KI, Andersson LC, Haglund C, Puolakkainen P, Wempe F, von Melchner H, Gradwohl G, Vanharanta S, Aaltonen LA, Saharinen J, Gentile M, Clarke A, Taipale J, Oliver G, Alitalo K (2008) Transcription factor PROX1 induces colon cancer progression by promoting the transition from benign to highly dysplastic phenotype. CANCER CELL, 13(5): 407-19
  60. Pramanik K, Trüpschuch S, Greiner A, Ruthardt M, Henschler R, Müller AM (2008) The aorta-gonad-mesonephros-derived stroma cell line DAS104-4 induces differentiation of leukemic cells. LEUKEMIA RES, 32(5): 781-9
  61. Schetelig J, Bornhäuser M, Schmid C, Hertenstein B, Schwerdtfeger R, Martin H, Stelljes M, Hegenbart U, Schäfer-Eckart K, Füssel M, Wiedemann B, Thiede C, Kienast J, Baurmann H, Ganser A, Kolb HJ, Ehninger G (2008) Matched unrelated or matched sibling donors result in comparable survival after allogeneic stem-cell transplantation in elderly patients with acute myeloid leukemia: a report from the cooperative German Transplant Study Group. J CLIN ONCOL, 26(32): 5183-91
  62. Schlenk RF, Döhner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L, Habdank M, Späth D, Morgan M, Benner A, Schlegelberger B, Heil G, Ganser A, Döhner H, German-Austrian--Acute-Myeloid-Leukemia-Study-Group (2008) Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. NEW ENGL J MED, 358(18): 1909-18
  63. Schnütgen F, Hansen J, De-Zolt S, Horn C, Lutz M, Floss T, Wurst W, Noppinger PR, von Melchner H (2008) Enhanced gene trapping in mouse embryonic stem cells. NUCLEIC ACIDS RES, 36(20): e133
  64. Seidel MG, Peters C, Wacker A, Northoff H, Moog R, Boehme A, Silling G, Grimminger W, Einsele H (2008) Randomized phase III study of granulocyte transfusions in neutropenic patients. BONE MARROW TRANSPL, 42(10): 679-84
  65. Smith CJ, Olsen CH, Mocroft A, Viard JP, Staszewski S, Panos G, Staub T, Blaxhult A, Vetter N, Lundgren JD (2008) The role of antiretroviral therapy in the incidence of pancreatitis in HIV-positive individuals in the EuroSIDA study. AIDS, 22(1): 47-56
  66. Sperling LE, Steinert G, Boutter J, Landgraf D, Hescheler J, Pollet D, Layer PG (2008) Characterisation of cholinesterase expression during murine embryonic stem cell differentiation. CHEM-BIOL INTERACT, 175(1-3): 156-60
  67. Spyridopoulos I, Erben Y, Brummendorf TH, Haendeler J, Dietz K, Seeger F, Kissel CK, Martin H, Hoffmann J, Assmus B, Zeiher AM, Dimmeler S (2008) Telomere gap between granulocytes and lymphocytes is a determinant for hematopoetic progenitor cell impairment in patients with previous myocardial infarction. ARTERIOSCL THROM VAS, 28(5): 968-74
  68. Stephan C, Just-Nübling G, Franck S, Bickel M, Shah PM, Babacan E, Staszewski S (2008) [No obvious difference in Streptococcus pneumoniae antibiotic resistance profiles--isolates from HIV-positive and HIV-negative patients]. MED KLIN, 103(2): 69-74
  69. Stephan C, Wolf T, Goetsch U, Bellinger O, Nisius G, Oremek G, Rakus Z, Gottschalk R, Stark S, Brodt HR, Staszewski S (2008) Comparing QuantiFERON-tuberculosis gold, T-SPOT tuberculosis and tuberculin skin test in HIV-infected individuals from a low prevalence tuberculosis country. AIDS, 22(18): 2471-9
  70. Stephan S, Schwarz H, Borchert A, Bussfeld D, Quak E, Simshaeuser-Knaub B, Teigelkamp S, Behrens F, Vitzthum F (2008) Tests for the measurement of factor VII-activating protease (FSAP) activity and antigen levels in citrated plasma, their correlation to PCR testing, and utility for the detection of the Marburg I-polymorphism of FSAP. CLIN CHEM LAB MED, 46(8): 1109-16
  71. Stürmer M, Carlebach A, Staszewski S, Linde R, Königs C, Doerr HW, Däumer M, Berger A (2008) Short communication: Different mutation patterns in subtype CRF06_cpx after mother-to-child transmission. AIDS RES HUM RETROV, 24(11): 1429-33
  72. Tashima K, Staszewski S, Nelson M, Rachlis A, Skiest D, Stryker R, Bessen L, Overfield S, Ruiz N, Wirtz V (2008) Efficacy and tolerability of long-term efavirenz plus nucleoside reverse transcriptase inhibitors for HIV-1 infection. AIDS, 22(2): 275-9
  73. Tickenbrock L, Hehn S, Sargin B, Choudhary C, Bäumer N, Buerger H, Schulte B, Müller O, Berdel WE, Müller-Tidow C, Serve H (2008) Activation of Wnt signalling in acute myeloid leukemia by induction of Frizzled-4. INT J ONCOL, 33(6): 1215-21
  74. Tickenbrock L, Hehn S, Sargin B, Evers G, Ng PR, Choudhary C, Berdel WE, Müller-Tidow C, Serve H (2008) Activation of Wnt signaling in cKit-ITD mediated transformation and imatinib sensitivity in acute myeloid leukemia. INT J HEMATOL, 88(2): 174-80
  75. Uysal H, Sehnert B, Nandakumar KS, Böiers U, Burkhardt H, Holmdahl R, Thunnissen MM (2008) The crystal structure of the pathogenic collagen type II-specific mouse monoclonal antibody CIIC1 Fab: structure to function analysis. MOL IMMUNOL, 45(8): 2196-204
  76. Vehreschild JJ, Böhme A, Reichert D, Kiehl MG, Arenz D, Pankraz K, Kochanek M, Ullmann AJ, Cornely OA (2008) Treatment of invasive fungal infections in clinical practice: a multi-centre survey on customary dosing, treatment indications, efficacy and safety of voriconazole. INT J HEMATOL, 87(2): 126-31
  77. von Hentig N, Babacan E, Lennemann T, Knecht G, Carlebach A, Harder S, Staszewski S, Haberl A (2008) The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors. J ANTIMICROB CHEMOTH, 62(3): 579-82
  78. von Hentig N, Förster AK, Kuczka K, Klinkhardt U, Klauke S, Gute P, Staszewski S, Harder S, Graff J (2008) Platelet-leucocyte adhesion markers before and after the initiation of antiretroviral therapy with HIV protease inhibitors. J ANTIMICROB CHEMOTH, 62(5): 1118-21
  79. von Hentig N, Kaykhin P, Stephan C, Babacan E, Stürmer M, Staszewski S, Lötsch J (2008) Decrease of atazanavir and lopinavir plasma concentrations in a boosted double human immunodeficiency virus protease inhibitor salvage regimen. ANTIMICROB AGENTS CH, 52(6): 2273-5
  80. von Hentig N, Nisius G, Lennemann T, Khaykin P, Stephan C, Babacan E, Staszewski S, Kurowski M, Harder S, Haberl A (2008) Pharmacokinetics, safety and efficacy of saquinavir/ ritonavir 1,000/100 mg twice daily as HIV type-1 therapy and transmission prophylaxis in pregnancy. ANTIVIR THER, 13(8): 1039-46
  81. Whitman SP, Ruppert AS, Radmacher MD, Mrozek K, Paschka P, Langer C, Baldus CD, Wen J, Racke F, Powell BL, Kolitz JE, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD (2008) FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. BLOOD, 111(3): 1552-9
  82. Wild N, Karl J, Grunert VP, Schmitt RI, Garczarek U, Krause F, Hasler F, van Riel PL, Bayer PM, Thun M, Mattey DL, Sharif M, Zolg W (2008) Diagnosis of rheumatoid arthritis: multivariate analysis of biomarkers. BIOMARKERS, 13(1): 88-105

Reviews

  1. Paschka P (2008) Core binding factor acute myeloid leukemia. SEMIN ONCOL, 35(4): 410-7
  2. Stephan C (2008) Experience with tenofovir disoproxil fumarate for antiretroviral therapy. EXPERT OPIN PHARMACO, 9(7): 1197-209
  3. von Hentig N (2008) [Measurement of the plasma concentration of antiretroviral drugs in HIV therapy]. DEUT MED WOCHENSCHR, 133(5): 191-5
  4. von Hentig N (2008) Atazanavir/ritonavir: a review of its use in HIV therapy. DRUG TODAY, 44(2): 103-32
  5. Wolf HH, Leithäuser M, Maschmeyer G, Salwender H, Klein U, Chaberny I, Weissinger F, Buchheidt D, Ruhnke M, Egerer G, Cornely O, Fätkenheuer G, Mousset S, Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO) (2008) Central venous catheter-related infections in hematology and oncology : guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). ANN HEMATOL, 87(11): 863-76

Supplement

  1. Giles FJ, DeAngelo DJ, Baccarani M, Deininger M, Guilhot F, Hughes T, Mauro M, Radich J, Ottmann O, Cortes J (2008) Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia. SEMIN ONCOL, 35(1 Suppl 1): S1-17; quiz S18-20

Habilitationen

  1. Bug G (2008) Präklinische und klinische Untersuchungen zur Wirkung des Histondeacetylase-Inhibitors Valproinsäure auf normale und leukämische Stamm- und Vorläuferzellen. Habilitation Universität
  2. Schnütgen F (2008) Hochdurchsatzverfahren zur konditionalen Mutagenese des Mausgenoms. Habilitation Universität


Dissertationen

  1. de Haas-Preissner K (2008) Laktatazidosen und symptomatische Hyperlaktatämie unter antiretroviraler Therapie bei HIV-nfizierten Patienten. Dissertation
  2. Demmer P (2008) Targeting von Oligomerisierungsdomänen der Leukämie-assoziierten Fusionsproteine PML/RAR? und PLZF/RAR? durch Peptide"". Dissertation
  3. Ebrahimian B (2008) Eine retrospektive Langzeitanalyse zu klinischen und molekularen Veränderungen bei Patienten mit rezidivierenden gastrointestinalen Stromatumoren unter der Therapie mit Imatinib. Dissertation
  4. Funk S (2008) Die Rolle der Proteintyrosinphosphatase-1B bei der Resistenzentwicklung ber-abl positiver Zellen nach Behandlung mit Imatinib. Dissertation
  5. Kamrath C (2008) Untersuchungen von Resistenzmechanismen und Prognosefaktorenbei Philadelphia Chromosom positiver akuter lymphatischer Leukämie und Blastenkrise bei chronischer myeloischer Leukämie unter der Therapie mit dem Tyrosinkinaseinhibitor Imatinib (Glivec®). Dissertation
  6. Nisius G (2008) Vergleich einer antiretroviralen Dreifach- mit einer Vierfach-Kombination bei nicht vorbehandelten HIV-infizierten Patienten mit deutlichem Immundefekt. Dissertation
  7. Scheuermann F (2008) Vergleich der oralen Candida-Besiedlung bei nierentransplantierten Patienten, Hämodialysepatienten und gesunden Probanden. Dissertation

Buchbeiträge

  1. Gökbuget N, Arnold R, Böhme A, Fietkau R, Freund M, Ganser A, Kneba M, Lipp T, Ludwig W D, Maschmeyer G, Messerer D, Rieder H, Thiel E, Hoelzer D (2008) Treatment of Adult ALL According to the Protocols of the German Multicenter Study Group for Adult ALL. In: Estey EH, Faderl SH, Kantarjian H (Hg.) Springer, Heidelberg New York, 167-176
  2. Gökbuget N, Hoelzer D (2008) Risk-adapted treatment of acute lymphoblastic leukemia. In: European Haematology Association (Hg.) Hematology Education, Wien, 64-70
  3. Gökbuget N, Hoelzer D (2008) HSCT for acute lymphoblastic leukaemia in adults. In: Apperley J, Carreras E, Gluckman E, Gratwohl A, Masszi T (Hg.) The EBMT Handbook, Florenz, 373-387
  4. Gökbuget N, Hoelzer D (2008) Acute lymphoblastic leukemia. In: Treöeaven J, Barrett AJ (Hg.) Churchill Livingstone - Elsevier, Edinburgh, 43-53
  5. Staszewski S (2008) Efavirenz. In: Dolin R; Masur M; Saag M (Hg.) AIDS Therapy. Elsevier Inc, USA, 247-262